The management of opioid dependence during pregnancy in rural and remote settings

CMAJ

Volumn 187, Issue 1, 2015, Pages E41-E46

  Jumah, Naana Afua ^a,b   Graves, Lisa ^c   Kahan, Meldon ^d  

^a Thunder Bay Regional Research Institute   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c NORTHERN ONTARIO SCHOOL OF MEDICINE   (Canada)

^d WOMEN S COLLEGE HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; METHADONE; MORPHINE; NARCOTIC ANALGESIC AGENT;

CANADIAN ABORIGINAL; DETOXIFICATION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; ETHNIC DIFFERENCE; FETAL WELL BEING; FETOPLACENTAL UNIT; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HEALTH CARE DELIVERY; HEROIN DEPENDENCE; HIGH RISK BEHAVIOR; HUMAN; MATERNAL CARE; METHADONE TREATMENT; MORBIDITY; OPIATE ADDICTION; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PREGNANCY; PREGNANCY OUTCOME; PREGNANT WOMAN; PRESCRIPTION DRUG DIVERSION; PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RURAL AREA; RURAL HEALTH CARE; SOCIAL STATUS; TREND STUDY; WITHDRAWAL SYNDROME; CHEMICALLY INDUCED; DISEASE MANAGEMENT; FEMALE; OPIOID-RELATED DISORDERS; PREGNANCY COMPLICATIONS; PROCEDURES; RURAL POPULATION; TELEMEDICINE;

ANALGESICS, OPIOID; DISEASE MANAGEMENT; FEMALE; HUMANS; OPIOID-RELATED DISORDERS; PREGNANCY; PREGNANCY COMPLICATIONS; RURAL POPULATION; TELEMEDICINE;

EID: 84920586592     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.131723     Document Type: Article

References (51)

1. International Narcotics Contro l Board. Narcotic drugs technical report: estimated world requirements for 2013- statistics for 2011. New York: United Nations; 2013.
2. Kaltenbach K, Berghella V, Finnegan L. Opioid dependence during pregnancy: effects and management. Obstet Gynecol Clin North Am 1998;25:139-51.
3. Fajemirokun-Odudeyi O, Sinha C, Tutty S, et al. Pregnancy outcome in women who use opiates. Eur J Obstet Gynecol Reprod Biol 2006;126:170-5.
4. Jones HE, Martin PR, Heil SH, et al. Treatment of opioid-dependent pregnant women: clinical and research issues. J Subst Abuse Treat 2008;35:245-59.
5. Winklbaur B, Kopf N, Ebner N, et al. Treating pregnant women dependent on opioids is not the same as treating pregnancy and opioid dependence: a knowledge synthesis for better treatment for women and neon ates. Addiction 2008;103:1429-40.
6. Borders TF,Booth BM. Research on rural residence and access to drug abuse services Where are we and where do we go? J Rural Health 2007 23(Suppl): 79-83.
7. Canadian Task Force on Preventive Health Care. New grades for recommendations from the Canadian Task Force on Preventive Health Care. CMAJ 2003;169:207-8.
8. What's urban? What's rural? Ottawa: Statistics Canada. Available: www41 .statcan.ca/2006/3119/ceb3119-002-eng.htm (accessed 2014 Apr. 21].
9. Buske L. Rural reality: analyzing medical life outside Canada's cities. Ottawa: Canadian Medical Association; 2008.
10. Shannon LM, Havens JR, Hays L. Examining differences in substance use among rural and urban pregnant women. Am J Addict 2010;19:467-73.
11. Heil SH, Sigmon SC, Jones HE, et al. Comparison of characteristics of opioid-using pregnant women in rural and urban settings. Am J Drug Alcohol Abuse 2008;34:463-71.
12. Wong S, Ordean A, Kahan M. Substance abuse in pregnancy. J Obstet Gynaecol Can 2011;33:367-84.
13. American College of Obstetricians and Gynecologists. Opioid abuse, dependence and addiction in pregnancy. Committee opinion 254. Obstet Gynecol 2012;119:1070-71.
14. Methadone program. Ottawa: Health Canada; 2011. Available: www.hc-sc.gc.ca/hc-ps/substancontrol/exemptions/methadone-eng .php (accessed 2013 July 29).
15. Section 56 class exemption for pharmacists. Ottawa: Health Canada; 2011. Available: www.hc-sc.gc.ca/hc-ps/substancontrol/pol/pol-docs/exemp-pharm-eng.php (accessed2013 July 29).
16. Lacroix I, Berrebi A, Garipuy D, et al. Buprenorphine versus methadone in pregnant opioid-dependent women: a prospective multicenter study. Eur J Clin Pharmacol 2011;67:1053-9.
17. Welle-Strand GK, Skurt veit S, Jones HE, et al. Neonatal outcomes following in utero exposure to methadone or buprenorphine: a national cohort study of opioid-Agonist treatment of pregnant women in Norway from 1996 to 2009. Drug Alcohol Depend 2013;12 7:200-6.
18. Fischer G, Ortner R, Rohrmeister K, et al. Methadone versus buprenorphine in pregnant addicts: a double-blind, double-dummy comparison study. Addiction 2006;101:275-81.
19. Jones HE, Kaltenbach K, Heil SH, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med 2010;363:2320-31.
20. Debelak K, Morrone WR, O'Grady KE, et al. Buprenorphine + naloxone in the treatment of opioid dependence during pregnancy-initial patient care and outcome data. Am J Addict 2013;22:252-4.
21. Potter JS, Marino EN, Hillhouse MP, et al. Buprenorphine/naloxone and methadone maintenance treatment outcomes for opioid analgesic, heroin, and combined users: findings from starting treatment with agonist replacement therapies (START). J Stud Alcohol Drugs 2013;74:605-13.
22. Hser YI, Saxon AJ, Huang D, et al. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial. Addiction 2014; 109: 79-87.
23. Hanford C. Buprenorphine/naloxone for opioid dependence: clinical practice guideline. Toronto: Centre for Addiction and Mental Health; 2012.
24. Lund IO, Fischer G, Welle-Strand GK, et al. A comparison of buprenorphine + naloxone to buprenorphine and methadone in the treatment of opioid dependence during pregnancy: maternal and neonatal outcomes. Subst Abuse 2013;7:61-74.
25. Daily Med. Naloxone hydrochloride [product monograph]. Bethesda (MD): National Institutes of Health; 2013. Available: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid =d524c0e5-A7c2-40b2-9eed-2caf71c787dc (accessed 201 3 Aug. 23).
26. Daily Med. Suboxone tablet [product monograph]. Bethesda (MD): National Institutes of Health; 2013. Available: http://dailymed .nlm .nih.gov/dailymed/lookup.cfm?setid=4b9b43c4-293e-4323-A1a1-9a2f6a16ac39. (accessed 2013 Aug. 23)
27. Daily Med. Suboxone soluble film [product monograph]. Bethesda (MD): National Institutes of Health; 2013. Available: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid =8a5edcf9-828c-4f97- b671-268ab13a8ecd(accessed 2013 Aug. 23)
28. Chase C. Supporting women using opiates in pregnancy: a guideline for primary care providers. Toronto: The Centre for Addiction and Mental Health Knowledge Exchange 2011. (accessed 2 013 Aug. 11). Available http://knowledgex.camh .net/opioid-Alert/2012/Documents/supporting-women-opiates-pregnancy511.pdf
29. Fischer G, Jagsch R, Eder H, et al. Comparison of methadone and slow-release morphine maintenance in pregnant addicts. Addiction 1999;94:231-9.
30. Schneider C, Fischer G, Diamant K, et al. Pregnancy and Drug Dependence. Wien Klin Wochenschr 1996;108:611-4.
31. Etzersdorfer P, Fischer G, Eder H, et al. Comparison of morphine and methadone maintenance in pregnant opiate addicts. NIDA Res Monogr 1997;178:343.
32. Ornoy A, Michailevskaya V, Lukas hov I, et al. The developmental outcome of children born to heroin-dependent mothers, raised at home or adopted. Child Abuse Negl 1996;20:385-96.
33. McCarthy JJ, Leamon MH, Parr MS, et al. High-dose methadone maintenance in pregnancy: maternal and neonatal outcomes. Am J Obstet Gynecol 2005;193:606-10.
34. Cleary BJ, Eogan M, O'Connell MP, et al. Methadone and perinatal outcomes: a prospective cohort study. Addiction 2012; 107:1482-92.
35. Albright B, de la Torre L, Skipper B, et al. Changes in methadone maintenance therapy during and after pregnancy. J Subst Abuse Treat 2011;41:347-53.
36. Blinick G, Wallach RC, Jerez E. Pregnancy in narcotics addicts treated by medical withdrawal. The methadone detoxification program. Am J Obstet Gynecol 1969;105:997-1003.
37. Rementeriá JL, Nunag NN. Narcotic withdrawal in pregnancy: stillbirth incidence with a case report. Am J Obstet Gynecol 1973; 116:1152-6.
38. Stern R. Th e pregnant addict: a study of 66 case histories, 1950- 1959. Am J Obstet Gynecol 1966;94:253-7.
39. Dashe JS, Sheffield JS, Olscher DA, et al. Relationship between maternal methadone dosage and neonatal withdrawal. Obstet Gynecol 2002;100:1244-9.
40. Dashe JS, Jackson GL , Olscher DA, et al. Opioid detoxification in pregnancy. Obstet Gynecol 1998;92:854-8.
41. Stewart RD, Nelson DB, Adhikari EH, et al. The obstetrical and neonatal impact of maternal opioid detoxification in pregnancy. Am J Obstet Gynecol 2013;209:267.e1-5.
42. Maas U, Kattner E, Weingart-Jesse B, et al. Infrequent neonatal opiate withdrawal following maternal methadone detoxification during pregnancy. J Perinat Med 1990;18:111-8.
43. Luty J, Nikolaou V, Bearn J. Is opiate detoxification unsafe in pregnancy? J Subst Abuse Treat 2003;24:363-7.
44. Jones HE, O'Grady KE, Malfi D, et al. Methadone maintenance vs. methadone taper during pregnancy: maternal and neonatal outcomes. Am J Addict 2008;17:372-86.
45. Finnegan LP. Treatment issues for opioid-dependent women during the perinatal period. J Psychoactive Drugs 1991;23: 191-201.
46. Kaltenbach K, Berghella V, Finnegan L. Opioid dependence during pregnancy. Effects and management. Obstet Gynecol Clin North Am 1998;25:139-51.
47. Uddin F. Hope in Fort Hope: First Nations community is winning the battle against prescription drug abuse. Can Fam Physician 2013;59:391-3.
48. Kelly L, Dooley J, Cromarty H, et al. Narcotic-exposed neonates in a First Nations population in Northwestern Ontario: incidence and implications. Can Fam Physician 2011;57:e 441-7.
49. Kiepek N,Hancock L,Toppozini D,et al. Facilitating medical withdrawal from opiates in rural Ontario Rural Remote Health 2012 12 2193.
50. Webster PC. Indigenous Canadians confront prescription opioid misuse. Lancet 2013;381:1447-8.
51. First Nations maternal support worker program first of its kind. Meno Ya Win News [Sioux Lookout (ON)] 2013;11:1-2.